---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-247599"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2024-10-30T23:59:59+00:00"
generated_at: "2026-05-30T08:28:58.172158+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Director Deneen Vojta resigns from Sensei Biotherapeutics board, effective Dec 31, 2024

## Summary
- Deneen Vojta, MD notified the Board of her resignation on October 25, 2024.
- Resignation effective December 31, 2024; cited personal reasons, no disagreement with Company.
- No replacement announced at this time.

## SEC filing metadata
- accession: 0001193125-24-247599
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2024-10-30T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312524247599/0001193125-24-247599-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312524247599/d805787d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-247599
- JSON: https://secwatch.observer/filing/0001193125-24-247599.json
- Plain text: https://secwatch.observer/filing/0001193125-24-247599.txt

## Key facts
- Executive change
  Deneen Vojta resigned as Director at Sensei Biotherapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: On October 25, 2024, Deneen Vojta, MD notified the Chair of the Board of Directors (the “Board”) of Sensei Biotherapeutics, Inc. (the “Company”) of her decision to resign from the Board, effective December 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1829802/000119312524247599/0001193125-24-247599-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.